{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["van Lierop ZY"],"funding":["Stichting MS Research"],"pagination":["2231-2242"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9679802"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(14)"],"pubmed_abstract":["<h4>Background</h4>Despite highly effective treatment strategies for patients with relapsing-remitting multiple sclerosis (RRMS), long-term neurodegeneration and disease progression are often considerable. Accurate blood-based biomarkers that predict long-term neurodegeneration are lacking.<h4>Objective</h4>To assess the predictive value of serum neurofilament-light (sNfL) and serum contactin-1 (sCNTN1) for long-term magnetic resonance imaging (MRI)-derived neurodegeneration in natalizumab-treated patients with RRMS.<h4>Methods</h4>sNfL and sCNTN1 were measured in an observational cohort of natalizumab-treated patients with RRMS at baseline (first dose) and at 3 months, Year 1, Year 2, and last follow-up (median = 5.2 years) of treatment. Disability progression was quantified using \"EDSS-plus\" criteria. Neurodegeneration was measured by calculating annualized percentage brain, ventricular, and thalamic volume change (PBVC, VVC, and TVC, respectively). Linear regression analysis was performed to identify longitudinal predictors of neurodegeneration.<h4>Results</h4>In total, 88 patients (age = 37 ± 9 years, 75% female) were included, of whom 48% progressed. Year 1 sNfL level (not baseline or 3 months) was associated with PBVC (standardized (std.) β = -0.26, <i>p</i> = 0.013), VVC (standardized β = 0.36, <i>p</i> < 0.001), and TVC (standardized β = -0.24, <i>p</i> = 0.02). For sCNTN1, only 3-month level was associated with VVC (standardized β = -0.31, <i>p</i> = 0.002).<h4>Conclusion</h4>Year 1 (but not baseline) sNfL level was predictive for long-term brain atrophy in patients treated with natalizumab. sCNTN1 level did not show a clear predictive value."],"journal":["Multiple sclerosis (Houndmills, Basingstoke, England)"],"pubmed_title":["Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis."],"pmcid":["PMC9679802"],"funding_grant_id":["18-358f"],"pubmed_authors":["van Dam M","Toorop AA","Noteboom S","Moraal B","Killestein J","van Lierop ZY","Steenwijk MD","Barkhof F","van Kempen ZL","Uitdehaag BM","Schoonheim MM","Teunissen CE"],"additional_accession":[]},"is_claimable":false,"name":"Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.","description":"<h4>Background</h4>Despite highly effective treatment strategies for patients with relapsing-remitting multiple sclerosis (RRMS), long-term neurodegeneration and disease progression are often considerable. Accurate blood-based biomarkers that predict long-term neurodegeneration are lacking.<h4>Objective</h4>To assess the predictive value of serum neurofilament-light (sNfL) and serum contactin-1 (sCNTN1) for long-term magnetic resonance imaging (MRI)-derived neurodegeneration in natalizumab-treated patients with RRMS.<h4>Methods</h4>sNfL and sCNTN1 were measured in an observational cohort of natalizumab-treated patients with RRMS at baseline (first dose) and at 3 months, Year 1, Year 2, and last follow-up (median = 5.2 years) of treatment. Disability progression was quantified using \"EDSS-plus\" criteria. Neurodegeneration was measured by calculating annualized percentage brain, ventricular, and thalamic volume change (PBVC, VVC, and TVC, respectively). Linear regression analysis was performed to identify longitudinal predictors of neurodegeneration.<h4>Results</h4>In total, 88 patients (age = 37 ± 9 years, 75% female) were included, of whom 48% progressed. Year 1 sNfL level (not baseline or 3 months) was associated with PBVC (standardized (std.) β = -0.26, <i>p</i> = 0.013), VVC (standardized β = 0.36, <i>p</i> < 0.001), and TVC (standardized β = -0.24, <i>p</i> = 0.02). For sCNTN1, only 3-month level was associated with VVC (standardized β = -0.31, <i>p</i> = 0.002).<h4>Conclusion</h4>Year 1 (but not baseline) sNfL level was predictive for long-term brain atrophy in patients treated with natalizumab. sCNTN1 level did not show a clear predictive value.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-18T17:07:33.042Z","creation":"2025-04-07T04:41:03.106Z"},"accession":"S-EPMC9679802","cross_references":{"pubmed":["36062492"],"doi":["10.1177/13524585221118676"]}}